Revelyx Bio’s Recombinant, Ready-to-Use Toxin Shows Promise for Glabellar Lines in Phase 2 Trial

Revelyx Bio, Inc.’s YY003, an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation, met its primary endpoints and key secondary endpoints in adults with moderate-to-severe glabellar lines, according to top-line results from a Phase 2 clinical trial.